These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Impact of glycoprotein VI and platelet adhesion on atherosclerosis--a possible role of fibronectin. Bültmann A; Li Z; Wagner S; Peluso M; Schönberger T; Weis C; Konrad I; Stellos K; Massberg S; Nieswandt B; Gawaz M; Ungerer M; Münch G J Mol Cell Cardiol; 2010 Sep; 49(3):532-42. PubMed ID: 20430036 [TBL] [Abstract][Full Text] [Related]
7. The GPVI-Fc fusion protein Revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times. Ungerer M; Li Z; Baumgartner C; Goebel S; Vogelmann J; Holthoff HP; Gawaz M; Münch G PLoS One; 2013; 8(8):e71193. PubMed ID: 23951109 [TBL] [Abstract][Full Text] [Related]
8. The metalloprotease, NN-PF3 from Naja naja venom inhibits platelet aggregation primarily by affecting α2β1 integrin. Kumar MS; Girish KS; Vishwanath BS; Kemparaju K Ann Hematol; 2011 May; 90(5):569-77. PubMed ID: 20957364 [TBL] [Abstract][Full Text] [Related]
9. Anti-glycoprotein VI treatment severely compromises hemostasis in mice with reduced alpha2beta1 levels or concomitant aspirin therapy. Grüner S; Prostredna M; Aktas B; Moers A; Schulte V; Krieg T; Offermanns S; Eckes B; Nieswandt B Circulation; 2004 Nov; 110(18):2946-51. PubMed ID: 15505105 [TBL] [Abstract][Full Text] [Related]
10. Platelet GPVI binds to collagenous structures in the core region of human atheromatous plaque and is critical for atheroprogression in vivo. Schulz C; Penz S; Hoffmann C; Langer H; Gillitzer A; Schneider S; Brandl R; Seidl S; Massberg S; Pichler B; Kremmer E; Stellos K; Schönberger T; Siess W; Gawaz M Basic Res Cardiol; 2008 Jul; 103(4):356-67. PubMed ID: 18431526 [TBL] [Abstract][Full Text] [Related]
11. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. Jakubowski JA; Payne CD; Weerakkody GJ; Brandt JT; Farid NA; Li YG; Naganuma H; Lachno DR; Winters KJ J Cardiovasc Pharmacol; 2007 Mar; 49(3):167-73. PubMed ID: 17414229 [TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetic/Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation. Renaud L; Lebozec K; Voors-Pette C; Dogterom P; Billiald P; Jandrot Perrus M; Pletan Y; Machacek M J Clin Pharmacol; 2020 Sep; 60(9):1198-1208. PubMed ID: 32500636 [TBL] [Abstract][Full Text] [Related]
13. The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke. Goebel S; Li Z; Vogelmann J; Holthoff HP; Degen H; Hermann DM; Gawaz M; Ungerer M; Münch G PLoS One; 2013; 8(7):e66960. PubMed ID: 23935828 [TBL] [Abstract][Full Text] [Related]
14. Implications of glycoprotein VI for theranostics. Gawaz M; Vogel S; Pfannenberg C; Pichler B; Langer H; Bigalke B Thromb Haemost; 2014 Jul; 112(1):26-31. PubMed ID: 24553806 [TBL] [Abstract][Full Text] [Related]
15. Local delivery of soluble platelet collagen receptor glycoprotein VI inhibits thrombus formation in vivo. Bültmann A; Herdeg C; Li Z; Münch G; Baumgartner C; Langer H; Kremmer E; Geisler T; May A; Ungerer M; Gawaz M Thromb Haemost; 2006 May; 95(5):763-6. PubMed ID: 16676064 [TBL] [Abstract][Full Text] [Related]
16. The dimeric platelet collagen receptor GPVI-Fc reduces platelet adhesion to activated endothelium and preserves myocardial function after transient ischemia in mice. Schönberger T; Ziegler M; Borst O; Konrad I; Nieswandt B; Massberg S; Ochmann C; Jürgens T; Seizer P; Langer H; Münch G; Ungerer M; Preissner KT; Elvers M; Gawaz M Am J Physiol Cell Physiol; 2012 Oct; 303(7):C757-66. PubMed ID: 22814400 [TBL] [Abstract][Full Text] [Related]